22nd Century Group, Inc. (XXII) Delivers 2.7Mln SPECTRUM Research Cigarettes under 5-Year Government Contract
7/31/2012 5:25:18 PM
22nd Century Group, a plant biotech company with proprietary technology for tobacco harm reduction and smoking cessation products, today announced it has delivered an additional 2.7 million SPECTRUM® research cigarettes.
The SPECTRUM line is comprised of a series of cigarette styles with a fixed amount of tar, but with varying nicotine yields. The product line features 24 styles, 11 regular and 13 menthol versions, with eight levels of nicotine content. The most prevalent style of SPECTRUM has approximately 97 percent less nicotine than “light” cigarettes on the market.
22nd Century developed SPECTRUM for NIDA, a department of the National Institutes of Health (NIH). Since the product is for independent research purposes only, SPECTRUM will not be sold as a commercial cigarette.
“As the only company in the world capable of producing cigarettes with such a wide range of nicotine levels, 22nd Century was chosen to supply its proprietary SPECTRUM research cigarettes as a subcontractor under a five-year federal government contract,” Joseph Pandolfino, 22nd Century’s CEO stated in the press release.
22nd Century said dozens of research studies will be conducted with SPECTRUM to observe smoking cessation; compare how different nicotine levels in cigarettes affect smoking behavior and exposure to smoke; and to determine whether there is a threshold nicotine level in cigarettes which does not produce dependence.
For more information visit www.xxiicentury.com
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net